Table 1.
Patient epidemiological data, medical disorders and treatments
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Early complications (< 30 d) |
Late complications (> 30 d) |
No complications | p-value (3–2) | p-value (4–2) | p-value (4–3) | ||||||
| n = 92 | % | n = 23 | % | n = 49 | % | n = 20 | % | |||||
| Age (years) | 67.2 ± 7.9 | 69.1 ± 8.3 | 67.2 ± 7.4 | 65.3 ± 8.5 | 0.34 | 0.14 | 0.35 | |||||
| BMI (kg/m^2) | 26.6 ± 3.4 | 27.0 ± 3.2 | 26.8 ± 3.2 | 25.9 ± 4.1 | 0.90 | 0.38 | 0.33 | |||||
| Gender | Male | 28 | 30.4 | 7 | 30.4 | 13 | 26.5 | 8 | 40.0 | 0.73 | 0.52 | 0.28 |
| Female | 64 | 69.6 | 16 | 69.5 | 36 | 73.5 | 12 | 60.0 | 0.73 | 0.52 | 0.28 | |
| ASA class | 1 | 1 | 1.0 | 0 | 0.0 | 0 | 0.0 | 1 | 5.0 | – | 0.29 | 0.12 |
| 2 | 62 | 67.3 | 13 | 56.5 | 35 | 71.4 | 14 | 70.0 | 0.22 | 0.37 | 0.91 | |
| 3 | 29 | 31.5 | 10 | 43.4 | 14 | 28.5 | 5 | 25.0 | 0.22 | 0.21 | 0.77 | |
| 4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | – | – | – | |
| Obesity | 20 | 21.7 | 4 | 17.3 | 11 | 22.4 | 5 | 25.0 | 0.63 | 0.55 | 0.82 | |
| Smoker | 26 | 31.7 | 6 | 30.0 | 12 | 28.5 | 8 | 40.0 | 0.91 | 0.52 | 0.38 | |
| Type 1 Diabetes | 8 | 8.9 | 4 | 8.6 | 4 | 8.6 | 0 | 0.0 | 0.29 | 0.05 | 0.18 | |
| Type 2 Diabetes | 11 | 11.5 | 5 | 12.7 | 6 | 12.7 | 0 | 0.0 | 0.26 | < 0.05 | 0.10 | |
| COPD | 15 | 16.4 | 6 | 26.0 | 7 | 14.5 | 2 | 10.0 | 0.25 | 0.18 | 0.62 | |
| Osteoporosis | 23 | 25.0 | 6 | 26.0 | 14 | 28.5 | 3 | 15.0 | 0.83 | 0.38 | 0.24 | |
| Neurological Disease | 4 | 4.3 | 0 | 0.0 | 4 | 8.1 | 0 | 0.0 | 0.16 | – | 0.19 | |
| Hypertension | 34 | 36.9 | 11 | 47.8 | 16 | 32.6 | 7 | 35.0 | 0.22 | 0.41 | 0.85 | |
| PM | 5 | 5.4 | 3 | 13.0 | 2 | 4.0 | 0 | 0.0 | 0.17 | 0.10 | 0.37 | |
| CA | 19 | 22.6 | 9 | 40.9 | 9 | 21.4 | 1 | 5.0 | 0.10 | < 0.05 | 0.10 | |
| RA | 7 | 7.6 | 2 | 8.6 | 4 | 8.1 | 1 | 5.0 | 0.94 | 0.64 | 0.65 | |
| Cortisone | 6 | 6.5 | 2 | 4.0 | 2 | 4.0 | 2 | 10.0 | 0.43 | 0.89 | 0.35 | |
| ASS | 7 | 7.6 | 1 | 10.2 | 5 | 10.2 | 1 | 5.0 | 0.41 | 0.92 | 0.49 | |
| Coumarin derivative | 8 | 8.6 | 4 | 17.3 | 2 | 4.0 | 2 | 10.0 | 0.06 | 0.50 | 0.35 | |
Abbreviations: BMI body mass index, ASA class American Society of Anesthesiologists, COPD chronic obstructive pulmonary disease, PM pacemaker, CA cardiac arrhythmias, RA rheumatoid arthritis, ASS acetylsalicylic acid, coumarin derivative – phenprocoumon. Statistical analyses regarding p-values were performed between the three columns/groups, i.e. early complications (2), late complications (3) and no complications (4); see superscripted numbers (significance at p < 0.05 or at p < 0.01)